Amorfix turnaround builds broad pipeline

What a difference a year makes. In 2010, Amorfix Life Sciences (TSX:AMF) pulled the plug on its lead blood test to detect the human variant of Creutzfeldt-Jakob disease, thereby halving its stock price and prompting a management shakeup. Today, Amorfix has built an innovative, early-stage product pipeline, including diagnostics and therapeutics for neurodegenerative diseases and [...]

Amorfix in ALS vaccine license with Pan-Provinical

Amorfix Life Sciences (TSX:AMF) has granted Pan-Provincial Vaccine Enterprise of Saskatoon exclusive worldwide rights to Amorfix’s lead amyotrophic lateral sclerosis vaccines, which have shown efficacy in animal models of ALS. Under the accord, Pan will develop vaccine formulations, finish preclinical studies for regulatory approvals and conduct clinical testing of the vaccines at their cost.  Upon [...]